Verju® Laser: The Most Effective, Painless, and Healthiest Treatment for Fat Removal and Body Sculpting

100% Automated

Save on staff costs and increase profits. The perfect no-contact treatment.

Quick & Convenient

Non-invasive 30 minute sessions with outstanding results.

No Downtime

Painless with no bruising, swelling, redness, or reported side-effects.

Erchonia’s non-thermal lasers are the only Low-Level Laser Therapy (LLLT) devices to be FDA Market Cleared for fat removal, cellulite reduction, and body sculpting – FDA Level One (510k) clearance is the ‘gold standard’, requiring placebo controlled, double blind, randomised, and multi-centre studies. The treatments are short, effective, and automated, allowing you to save on staff costs and increase profits. There is no associated pain, reported side effects, or downtime, and the technology is very safe with many important health benefits. We provide the training, ongoing support, and marketing, so you can focus on what matters most – your clients.


About Verju® Laser
About Verju® Laser
Proven to Give the Best Results

About Verju® Laser

The predecessor of Emerald™ – Verju® Laser – shares the same mechanisms of action, and is scientifically proven to be the most effective and healthiest treatment for fat loss, cellulite removal, and body contouring.

The device delivers fantastic results in short enjoyable sessions, and the treatments come with no side-effects or downtime.

Like Emerald™, Verju® is completely automated, allowing you to save on staff costs and increase profits. > Download Data Sheet

Most Advanced Laser Therapy Technology

How Verju® Laser Works

Verju® uses true green laser beams (monochromatic, collimated, and coherent) to create small transitory pores for the fatty liquids in fat cells to seep out. The fatty liquids are then naturally flushed out through the lymphatic system.

The result is that the fat cells shrink instead of being killed. When this happens, the shrunken fat cells begin to act and function like healthy lean cells, releasing the correct messages to the brain and creating a communication effect throughout the fat organ, causing other fat cells to release their content and return their hormone responses to the positive.

How Verju® Laser Works
How Verju® Laser Works
Case Studies

Europe’s First Emerald™ Clinic Makes £68,000+

“My clinic has recently been labelled ‘one of the fastest growing medium-sized medical institutions’ by Deloitte. Emerald fat removal laser has taken our previous success to another level. We earned more than 80,000 euros in the first 4 months. We definitely recommend Erchonia.” – Ogi Bagatin (CEO – Bagatin Clinics)

Emerald™ Testimonial by Ogi Bagatin
Emerald™ Testimonial by Ogi Bagatin

Before & After Treatment

AFTER
AFTER
AFTER
BEFORE
BEFORE
AFTER
AFTER
AFTER
BEFORE
BEFORE
AFTER
AFTER
AFTER
BEFORE
BEFORE
AFTER
AFTER
AFTER
BEFORE
BEFORE
AFTER
AFTER
AFTER
BEFORE
BEFORE
AFTER
AFTER
AFTER
BEFORE
BEFORE
AFTER
AFTER
AFTER
BEFORE
BEFORE
AFTER
AFTER
AFTER
BEFORE
BEFORE
AFTER
AFTER
AFTER
BEFORE
BEFORE

Recent Testimonials

From physicians and surgeons, to aesthetics clinics and weight loss centres, here’s what our clients have to say about our FDA Market Cleared non-thermal Low-Level Lasers.

“The Erchonia fat removal laser has helped multiple clients to lose 5 plus inches in their abdomen and over 12 inches in total measured abdomen, hip and thigh. Patients have been very happy with their results. We highly recommend Erchonia lasers.”

Dr. Reid Beaman

Roanoke Rapids Express Care

“I was attracted to using Verju in my clinic not only because it has robust clinical research supporting its success in fat loss, but also its safety profile and FDA approval. What I love is its simplicity and the amount of scientific evidence behind Cold Laser Therapy.”

Dr. Kashif Ali

Medical Weight Loss Ltd

“The Verju Laser is one of the most innovative products in the aesthetic industry. The fact of a completely pain free treatment with amazing results for the patients is convincing in any aspect. The support I have received from Erchonia has been excellent.”

Dr. med. Janine Pantzek

Hamburg, Germany

FAQs

How Do Erchonia® Lasers Work?

Erchonia® lasers create a small transitory pore for the fatty liquids in fat cells to seep out. The fatty liquids are then naturally flushed out through the lymphatic system.

The result is that the fat cells shrink instead of being killed. When this happens, the shrunken fat cells begin to act and function like healthy lean cells, releasing the correct messages to the brain and creating a communication effect throughout the fat organ, causing other fat cells to release their content and return their hormone responses to the positive.

Procedures that have been popular in the past (such as fat freezing) focus on the elimination of fat cells, but recent research has shown this approach to be ineffective, and in the worst-case scenario, providing counterproductive results as the fat may regenerate in other parts of the body, or worse, around the organs.

Erchonia® lasers effectively train fat cells to behave and react differently, and all without excessive heat or cooling.

What is the Scientific Evidence Behind Erchonia® Lasers?

All studies carried out to obtain FDA-approvals are Level One (510k), so are placebo controlled, double blind, randomised, and multi-centre – the most credible certifications of all fat loss devices on the market today.

The following list shows the clinical trials and an outline of their progress. As a company, to protect our intellectual assets, not all clinical trials we are involved with are made public so as to maintain our competitive advantage. As such, not all clinical trials are listed below.

Please note: There are hundreds of double blind medical studies confirming the effectiveness of Low-Level Laser Therapy (LLLT), and every year there are more than 250 new publications. Below is a list of Erchonia-specific studies for FDA-clearance.

1) Non-Invasive Dermatological Aesthetic Treatment for the Reduction of Body Circumference in Individuals With a Body Mass Index (BMI) of up to 40 kg / m² – 2019 – The data used to get this approval combined all previous data Erchonia® had on 20-40 BMI patients in the green laser studies below.

2) Non-Invasive Dermatological Aesthetic Treatment for the Reduction of Body Circumference — 2016.
FDA-clearance – K162578

3) Non-Invasive Dermatological Aesthetic Treatment for the Reduction of Circumference of Hips, Waist, Thighs and Upper Abdomen — 6 Week Treatment Protocol — 2014 — Sponsor and Monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.
FDA-clearance – K150446
To view NIH clinical trial records, click here.

4) Non-Invasive Dermatological Aesthetic Treatment for the Reduction of Circumference of Hips, Waist and Thighs — 2012 — Sponsor and Monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.
FDA-clearance – K143007
To view NIH clinical trial records, click here.

5) Non-Invasive Dermatological Aesthetic Treatment for Reduction of Circumference of Hips, Waist and Upper Abdomen When Applied to Individuals with a Body Mass Index (BMI) Between 30 kg/m2 and 40 kg/m2 — 2013 – Sponsor and Monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.
FDA-clearance – K142042
To view NIH clinical trial records, click here.

6) Non-Invasive Body Contouring Using GLS Laser – 532 nm (Green) Trade Name Verju — 2012 — Sponsor and Monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.
FDA-clearance – K123237
To view NIH clinical trial records, click here.

7) Appearance of Cellulite (Verju Laser System) — 2012 — Sponsor and Monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.
FDA-clearance – K130922
To view NIH clinical trial records, click here.

8) Arm Circumference Reduction of the Upper Arms — 2011 — Sponsor and Monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.
Study results used to obtain FDA-clearance – K120257
To view NIH clinical trial records, click here.

9) Non-Invasive Fat Reduction and Body Contouring – Laser Scanner Waist, Hips, and Thighs — 2009 — Sponsor and Monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.
Study results used to obtain FDA-clearance – K082609
To view NIH clinical trial records, click here.

10) Low-Level Laser Light Therapy as an Aid to Liposuction and Reduction of Pain Associated With Surgery — 2004 — Sponsor and Monitor, IRB approved, double blind, placebo controlled, multi-site, clinical study.
Study results used to obtain FDA-clearance – K041139
To view NIH clinical trial records, click here.

What is the Difference Between Erchonia® and Other Technologies in This Market?

Erchonia® lasers have been scientifically proven to be the most effective fat loss devices on the market today. The lasers are completely pain free, have been clinically proven to be safe and effective, and provide relaxing treatments with numerous health and wellness benefits for the patient (which is more important than ever in the current climate). Furthermore, there have been no reported side effects or adverse reactions with our technology, and the system is truly inspired by the simplicity of nature, differentiating us from competing products in the sector.

Erchonia® lasers can be used to treat small pockets of fat or larger surface areas, and are FDA Market Cleared for overall circumferential reduction on patients up to 40 BMI. Level One (510k) FDA-clearance is the gold standard, and is one of the hardest certificates to obtain, requiring placebo controlled, double blind, randomised, and multi-centre studies. Many competing companies advertise their products as ‘clinically proven’, guaranteeing ‘instant results’. However, these claims are often not backed by comprehensive clinical evidence.

It is also sometimes the case that competing technologies are marketed as ‘FDA-cleared’, but this clearance is quite weak or not related to fat loss. For example, perhaps the clearance is for wrinkles and rhytids, or for temporary fat reduction. We always recommend that you ask for details of the FDA-clearances and make an informed decision – pay particular attention to the scope of the clearance, how many patients participated, whether it was placebo controlled, double blind, and randomised, how many peer reviewed published articles they have, and what the adverse reactions / side effects were (we would be happy to provide this information for you).

Statements From the FDA

  • Emerald – 6 inches / 15.24 cm average reduction in waist, hips, and upper abdomen (51.33 mm off waist) – 1 month.
  • Verjú (Emerald Predecessor) – 11.48 cm reduction in waist, hips, and thighs – 2 weeks.
  • Cool Sculpting / Zeltiq – No reduction. Appearance claim only (1.78 – 2.66 mm at 4 months).
  • Liposonix (Ultrasound) – 1 inch loss at 4 months.
  • Ultrashape (Ultrasound) – 1 inch loss at 4 months.
  • Sculpsure (Thermal Laser) – 1.785 mm at 12 weeks.
What is a Non-Thermal Laser? (Technical Explanation)

To understand the properties of non-thermal lasers, it is first important to distinguish between High-Level Laser Therapy (HLLT) and Low-Level Laser Therapy (LLLT):

  • HLLT devices are classified as ‘Class IV Lasers’ by the FDA in virtue of having a power output that’s greater than 500mW (i.e. high risk of hazard).
  • LLLT devices are classified as either ‘Class IIIB Lasers’, ‘Class IIIR Lasers’, or ‘Class II Lasers’ in virtue of having a power output of 5-500mW, 1-5mW, or <1mW respectively (i.e. lower risk of hazard).

The vast majority of HLLT devices have longer near-infrared (NIR) wavelengths – there is a common misconception, often propagated by the manufacturers of such devices, that high power with longer wavelengths results in:

  1. Deeper penetration, allowing for the treatment of a wider range of conditions.
  2. More efficacious results (due to the delivery of more energy into the cells).

This however, is not correct for the following well-documented reasons:

  1. Due to the high absorption rate of laser light by water at wavelengths greater than 950nm, most of the energy produced at this wavelength (or above) is absorbed before penetrating the dermis.
  2. The key principle behind Laser Therapy is to generate therapeutic effects by stimulating and enhancing specific biochemical processes within cells. More specifically, utilising the first law in photochemistry (Grotthuss-Draper law), laser energy is transferred to cytochrome c oxidase (CcO) – a respiratory energy-transducing enzyme which is involved in the electron transport chain in mitochondria. This energy transfer causes photodissociation of inhibitory nitric oxide from CcO, leading to an enhancement of enzyme activity, electron transport, mitochondrial respiration, and adenosine triphosphate (ATP) production. Consequently, by altering the cellular redox state, Laser Therapy induces the activation of numerous intracellular signalling pathways, and alters the affinity of transcription factors concerned with cell proliferation, survival, repair, and regeneration. However, there is an optimal ‘dose’ of laser energy (typically 2-4 joules / cm²) required for stimulating and enhancing these desired biochemical processes – HLLT devices exceed this optimal level.

Put simply, HLLT devices deliver too much energy at inefficient wavelengths, resulting in a lack of efficacy and increased costs.

To add to this, the high outputs used by such devices produce painful heat sensations, further limiting their scope of treatment.

In essence, HLLT devices should only be used for laser surgery and tissue ablation – the high outputs are effective for cell destruction, but are not suited for therapeutic purposes, contrary to the claims of Class IV manufacturers.

LLLT devices, on the other hand, aim to deliver energy via low output, short wavelength beams of light. The general theory is that this approach transfers the optimal amount of energy for stimulating and enhancing cell function, while not damaging cells or producing painful heat sensations.

Within the LLLT sector however, some of the higher-output devices still generate heat / pain. Furthermore, many devices are advertised as ‘lasers’, when in fact they are Light Emitting Diodes (LEDs) or Superluminescent Diodes (SLDs). In contrast to LEDs or SLDs, ‘true’ lasers generate monochromatic, collimated, and coherent beams of light. That is, the light emitted by a true laser is composed from photons that have the same wavelength (monochromatic), travel in the same direction / do not disperse (collimated), and are in phase in space and time (coherent). These three properties of true lasers make them the most effective and efficient LLLT devices.

To separate Erchonia® from such technologies, and from HLLT more generally, we say that our lasers are ‘non-thermal, true lasers’. That is, Erchonia® lasers do not produce any heat or painful sensations, and are monochromatic, collimated, and coherent.

How is Erchonia® Laser Therapy Administered?

There are two basic steps when administering Erchonia® treatments. First, we find the most severe areas of subcutaneous fat or cellulite. Then, we use the diodes to target this area, positioning them around 9 – 15 cm away from the skin. This optimises exposure to the generated beams, and treats the target area whilst the client relaxes.

Are There Any Conditions Which Would Prevent Patients From Receiving the Treatments?

There are no code regulated contraindications, however, since there are no long-term evaluations on certain conditions, we do not recommend using Erchonia® lasers on pregnant women, clients with a pacemaker, or clients with photosensitive epilepsy. We also do no recommend using the devices over an area of known cancer.

How Long do the Results Last?

The treatments are officially labelled as ‘non-temporary’ by the FDA, so as long as your clients lead a normal to healthy lifestyle, their results will continue. To give an example, if your clients consume 4000 calories per day, although they will lose inches during the Erchonia® treatments, they may quickly put these inches back on.

We generally recommend that you promote small lifestyle changes along with the Erchonia® course, with the option of maintenance treatments if required.

How Long are the Treatments?

Erchonia® treatments are just 30 minutes long and fully automated, allowing you to save on staff costs and increase profits.

How Many Treatments Are Required?

Your clients should see improvements after the very first session, and the results will continue to improve with each treatment.

However, the number of treatments that your clients will require depends on their aims, objectives, lifestyle, medical history, and any medication that they may be on – in general, most patients will need 6+ sessions, with one, two, or three treatments per week.

What Areas Can be Treated?

Erchonia® lasers treat overall body circumference while also allowing your clients to target stubborn areas of fat and cellulite.

Most people who undergo the treatments focus on their midriff and thighs, but the device can also target any area of subcutaneous fat, including bra strap, upper arms, jowls, knees, and more.

Please examine the image below for the possible treatment options:

Areas of Fat and Cellulite that can be treated with Erchonia lasers
What do Erchonia® Lasers Treat and How Are They Used?

Erchonia® lasers are used in many areas, such as 360-degree fat loss, body sculpting, cellulite reduction, pain management, pre / postsurgical healing, pre / rehabilitation, and nail and skin pathologies (e.g. onychomycosis (nail fungus), acne, and more).

Not only do our lasers treat specifics, but they also empower the body to function efficiently due to the beneficial effects they have on our cells.

Is There Any Pain or Downtime Associated With Erchonia® Technologies?

Erchonia® technologies do not have any downtime or associated pain, and there are no recorded side effects or adverse reactions – Erchonia® lasers inspire our bodies to act to produce ‘a better you’.

Why Choose Erchonia®?

World Leaders in Laser Therapy Technology

With over 25 years of experience, 16,000+ devices in the market, and 18 FDA-clearances, Erchonia® Corporation are world leaders in Laser Therapy technology. Our range of non-thermal Low-Level Laser Therapy (LLLT) devices are used in many areas, including pain relief, fat removal, cellulite reduction, fungal nail treatment, and more. Based in the UK, Erchonia Lasers Ltd are a subsidiary organisation. We provide personal support to companies in Europe, Middle East, and Africa… Read More

About Erchonia® Corporation
About Erchonia® Corporation

91% Customer Satisfaction Rating

Our clients say it all: best products, service, training, and support.

Over 25 Years of Experience

Founded in 1996 – first Low-Level Laser in the world to gain FDA market clearance.

18 FDA (Level One 510k) Clearances

Proven by placebo controlled, double blind, randomised, and multi-centre studies.

16,000+ Devices in the Market

Leaders in the field with over $5 million invested in R&D at any one time.